NCT01432600 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 36
- group Id
- BG002
- value
- 34
- group Id
- BG003
- value
- 80
- units
- Participants
- groups
- description
- Phase I: Pomalidomide, high dose dexamethasone and oral cyclophosphamide.
- id
- BG000
- title
- A: Dose Escalation of Cyclophosphamide
- description
- Phase II: Pomalidomide and high dose dexamethasone. Crossover Arm D is a part of Arm B. Arm D was opened later to accommodate requested transfers from Arm B. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician. Arm D participants may be referenced separately in some Outcome Measures.
- id
- BG001
- title
- B: Pomalidomide and Dexamethasone
- description
- Phase II: Pomalidomide high dose dexamethasone and oral cyclophosphamide.
- id
- BG002
- title
- C: Pomalidomide, Dexamethasone, Cyclophosphamide
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 39
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 41
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 44
- upper Limit
- 73
- value
- 69
- group Id
- BG001
- lower Limit
- 50
- upper Limit
- 78
- value
- 64
- group Id
- BG002
- lower Limit
- 47
- upper Limit
- 80
- value
- 62
- group Id
- BG003
- lower Limit
- 44
- upper Limit
- 80
- value
- 63
- dispersion Type
- FULL_RANGE
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 32
- title
- Female
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 48
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 36
- group Id
- BG002
- value
- 34
- group Id
- BG003
- value
- 80
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- population Description
- All participants. Arm D (a part of Arm B) started in July 2012 when, per protocol guidelines, 17 participants from Arm B elected to crossover to Arm D. Some measures may include arm D, making the total of participants evaluated higher.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 36
- group Id
- BG002
- value
- 34
- group Id
- BG003
- value
- 80
- units
- Participants
- groups
- description
- Phase I: Pomalidomide, high dose dexamethasone and oral cyclophosphamide.
- id
- BG000
- title
- A: Dose Escalation of Cyclophosphamide
- description
- Phase II: Pomalidomide and high dose dexamethasone. Crossover Arm D is a part of Arm B. Arm D was opened later to accommodate requested transfers from Arm B. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician. Arm D participants may be referenced separately in some Outcome Measures.
- id
- BG001
- title
- B: Pomalidomide and Dexamethasone
- description
- Phase II: Pomalidomide high dose dexamethasone and oral cyclophosphamide.
- id
- BG002
- title
- C: Pomalidomide, Dexamethasone, Cyclophosphamide
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 39
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 41
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 44
- upper Limit
- 73
- value
- 69
- group Id
- BG001
- lower Limit
- 50
- upper Limit
- 78
- value
- 64
- group Id
- BG002
- lower Limit
- 47
- upper Limit
- 80
- value
- 62
- group Id
- BG003
- lower Limit
- 44
- upper Limit
- 80
- value
- 63
- dispersion Type
- FULL_RANGE
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 32
- title
- Female
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 48
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 36
- group Id
- BG002
- value
- 34
- group Id
- BG003
- value
- 80
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- population Description
- All participants. Arm D (a part of Arm B) started in July 2012 when, per protocol guidelines, 17 participants from Arm B elected to crossover to Arm D. Some measures may include arm D, making the total of participants evaluated higher.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle